Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1986 1
1987 1
1989 2
1991 2
1992 4
1993 9
1994 9
1995 17
1996 9
1997 6
1998 7
1999 8
2000 6
2001 1
2002 9
2003 10
2004 7
2005 4
2006 9
2007 6
2008 10
2009 13
2010 12
2011 11
2012 13
2013 17
2014 17
2015 14
2016 18
2017 30
2018 34
2019 35
2020 30
2021 39
2022 38
2023 34
2024 15

Text availability

Article attribute

Article type

Publication date

Search Results

455 results

Results by year

Filters applied: . Clear all
Page 1
Miró Ò, Gil V. Miró Ò, et al. Among authors: gil v. Chest. 2018 Mar;153(3):766. doi: 10.1016/j.chest.2018.01.004. Chest. 2018. PMID: 29519306 No abstract available.
Targeting the p300/CBP Axis in Lethal Prostate Cancer.
Welti J, Sharp A, Brooks N, Yuan W, McNair C, Chand SN, Pal A, Figueiredo I, Riisnaes R, Gurel B, Rekowski J, Bogdan D, West W, Young B, Raja M, Prosser A, Lane J, Thomson S, Worthington J, Onions S, Shannon J, Paoletta S, Brown R, Smyth D, Harbottle GW, Gil VS, Miranda S, Crespo M, Ferreira A, Pereira R, Tunariu N, Carreira S, Neeb AJ, Ning J, Swain A, Taddei D; SU2C/PCF International Prostate Cancer Dream Team; Schiewer MJ, Knudsen KE, Pegg N, de Bono JS. Welti J, et al. Among authors: gil vs. Cancer Discov. 2021 May;11(5):1118-1137. doi: 10.1158/2159-8290.CD-20-0751. Epub 2021 Jan 11. Cancer Discov. 2021. PMID: 33431496 Free PMC article.
HER3 Is an Actionable Target in Advanced Prostate Cancer.
Gil V, Miranda S, Riisnaes R, Gurel B, D'Ambrosio M, Vasciaveo A, Crespo M, Ferreira A, Brina D, Troiani M, Sharp A, Sheehan B, Christova R, Seed G, Figueiredo I, Lambros M, Dolling D, Rekowski J, Alajati A, Clarke M, Pereira R, Flohr P, Fowler G, Boysen G, Sumanasuriya S, Bianchini D, Rescigno P, Aversa C, Tunariu N, Guo C, Paschalis A, Bertan C, Buroni L, Ning J, Carreira S, Workman P, Swain A, Califano A, Shen MM, Alimonti A, Neeb A, Welti J, Yuan W, de Bono J; PCF/SU2C International Prostate Cancer Dream Team. Gil V, et al. Cancer Res. 2021 Dec 15;81(24):6207-6218. doi: 10.1158/0008-5472.CAN-21-3360. Epub 2021 Nov 9. Cancer Res. 2021. PMID: 34753775 Free PMC article.
IL-23 secreted by myeloid cells drives castration-resistant prostate cancer.
Calcinotto A, Spataro C, Zagato E, Di Mitri D, Gil V, Crespo M, De Bernardis G, Losa M, Mirenda M, Pasquini E, Rinaldi A, Sumanasuriya S, Lambros MB, Neeb A, Lucianò R, Bravi CA, Nava-Rodrigues D, Dolling D, Prayer-Galetti T, Ferreira A, Briganti A, Esposito A, Barry S, Yuan W, Sharp A, de Bono J, Alimonti A. Calcinotto A, et al. Among authors: gil v. Nature. 2018 Jul;559(7714):363-369. doi: 10.1038/s41586-018-0266-0. Epub 2018 Jun 27. Nature. 2018. PMID: 29950727 Free PMC article.
Digoxin: friend or foe?
Llorens P, Gil V. Llorens P, et al. Among authors: gil v. Emergencias. 2023 Oct;35(5):325-327. doi: 10.55633/s3me/E022.2023. Emergencias. 2023. PMID: 37801413 Free article. English, Spanish. No abstract available.
Midazolam versus morphine in acute cardiogenic pulmonary oedema: results of a multicentre, open-label, randomized controlled trial.
Domínguez-Rodríguez A, Suero-Mendez C, Burillo-Putze G, Gil V, Calvo-Rodriguez R, Piñera-Salmeron P, Llorens P, Martín-Sánchez FJ, Abreu-Gonzalez P, Miró Ò; MIMO (MIdazolam versus MOrphine) Trial Investigators. Domínguez-Rodríguez A, et al. Among authors: gil v. Eur J Heart Fail. 2022 Oct;24(10):1953-1962. doi: 10.1002/ejhf.2602. Epub 2022 Jul 16. Eur J Heart Fail. 2022. PMID: 35780488 Free article. Clinical Trial.
COVID-19 and cardiovascular comorbidities: An update.
Teixeira R, Santos M, Gil V. Teixeira R, et al. Among authors: gil v. Rev Port Cardiol (Engl Ed). 2020 Aug;39(8):417-419. doi: 10.1016/j.repce.2020.06.002. Epub 2020 Dec 16. Rev Port Cardiol (Engl Ed). 2020. PMID: 38620731 Free PMC article. No abstract available.
Emerging technologies: general discussion.
Bardow A, Bizzarri C, Cao XE, Cowan AJ, Cummings C, Del Angel Hernandez V, Doan H, Dowson G, Ghosh S, Gil V, Gugujonovic K, Kamali AR, König M, Leitner W, Luo J, Madhav D, Maneiro M, Manyar H, McCord S, Moore E, North M, Pant D, Perry S, Poon J, Rossi L, Ruiz Esquius J, Schreiber M, Shozi M, Sick V, Styring P, Tanveer W, Thomas O, Whiston K, Yu E. Bardow A, et al. Among authors: gil v. Faraday Discuss. 2021 Jul 16;230(0):388-412. doi: 10.1039/d1fd90048j. Faraday Discuss. 2021. PMID: 34231609 No abstract available.
Computational Enzyme Design at Zymvol.
Monza E, Gil V, Lucas MF. Monza E, et al. Among authors: gil v. Methods Mol Biol. 2022;2397:249-259. doi: 10.1007/978-1-0716-1826-4_13. Methods Mol Biol. 2022. PMID: 34813068
CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo.
Alajati A, D'Ambrosio M, Troiani M, Mosole S, Pellegrini L, Chen J, Revandkar A, Bolis M, Theurillat JP, Guccini I, Losa M, Calcinotto A, De Bernardis G, Pasquini E, D'Antuono R, Sharp A, Figueiredo I, Nava Rodrigues D, Welti J, Gil V, Yuan W, Vlajnic T, Bubendorf L, Chiorino G, Gnetti L, Torrano V, Carracedo A, Camplese L, Hirabayashi S, Canato E, Pasut G, Montopoli M, Rüschoff JH, Wild P, Moch H, De Bono J, Alimonti A. Alajati A, et al. Among authors: gil v. J Clin Invest. 2020 May 1;130(5):2435-2450. doi: 10.1172/JCI131133. J Clin Invest. 2020. PMID: 32250342 Free PMC article.
455 results